Transgene SA TRGNF
0.75 USD 0.00 (+0.00%)
At closeNov 3, 2026, 4:00 PM EST
0.80 Day range 0.80
0.70 52-week range 1.08
- YTD
- -25.50%
- 1 year
- +6.43%
- Market cap
- 207.30M
- EPS (ttm)
- -0.20
- YTD return
- -25.50%
- 1-year return
- +6.43%
- Volume
- 1.00K
- Avg volume
- 26
- Open
- 0.80
- Previous close
- 0.745
- Day's range
- 0.80 – 0.80
- 52-week range
- 0.70 – 1.08
2Y -0.8450 (-53.14%)
News
Transgene SA (TRGNF) Discusses Progress in Individualized Neoantigen Therapeutic Vaccines and Expansion into Early-Stage NSCLC Transcript 
Transgene SA (TRGNF) Q4 2025 Earnings Call Transcript 
Transgene announces the resume of trading of its shares on Euronext Paris as of the opening of the markets 
Correction: Transgene Announces the Temporary Suspension of Trading of its Shares on Euronext Paris 
Transgene Announces the Temporary Suspension of Trading of its Shares on Euronext Paris 
Transgene SA (TRGNF) Discusses TG4050 Phase I Immunological Data in Head and Neck Cancer from SITC Presentation Transcript 
Transgene and BioInvent's Armed Oncolytic Virus BT-001 Shows Positive Local, Abscopal, and Sustained Antitumoral Activity in Advanced Refractory Tumors 
Transgene and BioInvent's Armed Oncolytic Virus BT-001 Shows Positive Local, Abscopal, and Sustained Antitumoral Activity in Advanced Refractory Tumors 
Transgene and BioInvent to Present Translational Data and Updated Clinical Results on Armed Oncolytic Virus BT-001, at ESMO 2025 
Transgene and BioInvent to Present Translational Data and Updated Clinical Results on Armed Oncolytic Virus BT-001, at ESMO 2025
Your note
Sign in to keep a note on TRGNF — it syncs with the Stock Master app.